Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Resist Updat. 2006 Jun;9(3):157-73. Epub 2006 Jul 5.

Therapeutic potential of nitric oxide in cancer.

Author information

1
Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, 10833 Le Conte Avenue, A2-060 CHS, Los Angeles, CA, 90095-1747, USA. bbonavida@mednet.ucla.edu <bbonavida@mednet.ucla.edu>

Abstract

In recent years, several novel approaches have been developed to overcome tumor cell resistance to conventional therapeutics. Such approaches include genetic manipulations, vaccine development and exploitation of the anti-tumor host immune response. The overall development of tumor cell resistance to therapeutics is, in large part, the result of the ability of tumor cells to develop specific mechanisms to overcome cell death or apoptosis. Therefore, the possibility to interfere selectively in the regulation of the apoptotic signaling pathways may result in either the direct induction of cell death and/or sensitization of the cells to cytotoxic stimuli. A novel approach based on modifying gene products that regulate resistance to apoptosis involves nitric oxide (NO). NO is a ubiquitous molecule with diverse cellular effects that depend on the source, concentration, latency, cell type and phenotype. This review describes the role played by NO in cancer including carcinogenesis, pathogenesis, angiogenesis, chemoprevention and as a novel therapeutic to overcome resistance when used alone or as a sensitizing agent used in combination with other therapeutics.

PMID:
16822706
DOI:
10.1016/j.drup.2006.05.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center